AstraZeneca's Baxdrostat meets main goal in high blood pressure study

Core Viewpoint - AstraZeneca's drug Baxdrostat successfully met the primary endpoint in a late-stage study for patients with treatment-resistant hypertension [1] Group 1 - The study focused on patients suffering from high blood pressure that is resistant to standard treatments [1] - The successful outcome of the study may enhance AstraZeneca's position in the hypertension treatment market [1]